Amarin Corp Plcuk (AMRN) Gains from Investment Securities (2011 - 2026)
Amarin Corp Plcuk (AMRN) posted quarterly Gains from Investment Securities of -$56000.0 for Q1 2026, down 105.0% YoY from $1.1 million in Q1 2025, and down 460.0% sequentially from -$10000.0 in Q4 2025.
Amarin Corp Plcuk (AMRN) Gains from Investment Securities (2011 - 2026) Analysis & Trends
Amarin Corp Plcuk has disclosed Gains from Investment Securities across 16 years of filings, most recently posting -$56000.0 for Q1 2026.
- In Q1 2026, Gains from Investment Securities fell 105.0% year-over-year to -$56000.0; the TTM figure through Mar 2026 stood at $2.7 million (down 36.63% YoY), while the FY2025 annual figure was $4.1 million, down 85.33% from the prior year.
- Gains from Investment Securities declined to -$56000.0 in Q1 2026, from -$10000.0 in the prior quarter.
- Over the last five years, Gains from Investment Securities for AMRN reached as high as $30.8 million in Q3 2025 and fell as low as -$56000.0 in Q1 2026.
- The 5-year median for Gains from Investment Securities is $851549.0 (2023), against an average of $2.6 million.
- Annual changes were most pronounced in 2024 — Gains from Investment Securities jumped 18611.11% — and 2026, when it plunged 105.0%.
- A 5-year view of Gains from Investment Securities shows it stood at $2.5 million in 2022, then tumbled by 99.64% to $9000.0 in 2023, then jumped by 18611.11% to $1.7 million in 2024, then tumbled by 100.59% to -$10000.0 in 2025, then tumbled by 460.0% to -$56000.0 in 2026.
- According to Business Quant data, Gains from Investment Securities over the past three periods registered -$56000.0, -$10000.0, and $30.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.82 Mn |
| Mar 31, 2026 | 30.82 Mn |
| Dec 31, 2025 | -10,000.00 |
| Dec 31, 2025 | -10,000.00 |
| Sep 30, 2025 | 30.77 Mn |
| Sep 30, 2025 | 30.77 Mn |
| Jun 30, 2025 | 750,000.00 |
| Jun 30, 2025 | 750,000.00 |
| Mar 31, 2025 | 1.69 Mn |
| Mar 31, 2025 | 1.69 Mn |
| Dec 31, 2024 | 1.68 Mn |
| Dec 31, 2024 | 1.68 Mn |
| Sep 30, 2024 | 227,380.00 |
| Sep 30, 2024 | 227,380.00 |
| Jun 30, 2024 | 1.09 Mn |
| Jun 30, 2024 | 1.09 Mn |
| Mar 31, 2024 | -36,000.00 |
| Mar 31, 2024 | -36,000.00 |
| Dec 31, 2023 | 9,000.00 |
| Dec 31, 2023 | 9,000.00 |